CYTK
Price
$62.33
Change
-$0.53 (-0.84%)
Updated
Oct 22 closing price
Capitalization
8.67B
13 days until earnings call
Intraday BUY SELL Signals
NAMS
Price
$21.58
Change
+$0.09 (+0.42%)
Updated
Oct 22 closing price
Capitalization
2.58B
13 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

CYTK vs NAMS

CYTK vs NAMS Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
CYTK vs. NAMS commentary
Oct 23, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CYTK is a StrongBuy and NAMS is a Hold.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for CYTK with price predictions
Oct 22, 2026

CYTK's RSI Oscillator ascends from oversold territory

The RSI Oscillator for CYTK moved out of oversold territory on October 14, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 24 similar instances when the indicator left oversold territory. In 19 of the 24 cases the stock moved higher. This puts the odds of a move higher at 79%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 52 of 68 cases where CYTK's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 76%.

The Momentum Indicator moved above the 0 level on October 20, 2026. You may want to consider a long position or call options on CYTK as a result. In 78 of 100 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 78%.

The Moving Average Convergence Divergence (MACD) for CYTK just turned positive on October 13, 2026. Looking at past instances where CYTK's MACD turned positive, the stock continued to rise in 44 of 57 cases over the following month. The odds of a continued upward trend are 77%.

Following a +3.23% 3-day Advance, the price is estimated to grow further. Considering data from situations where CYTK advanced for three days, in 215 of 296 cases, the price rose further within the following month. The odds of a continued upward trend are 73%.

CYTK may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The 50-day moving average for CYTK moved below the 200-day moving average on October 19, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CYTK declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 78%.

The Aroon Indicator for CYTK entered a downward trend on October 19, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 19 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 61 (best 1 - 100 worst), indicating steady price growth. CYTK’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 74 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CYTK’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.

The Tickeron Valuation Rating of 92 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: CYTK's P/B Ratio (-49.948) is slightly lower than the industry average of (2.973). P/E Ratio (-8.633) is within average values for comparable stocks, (-1.705). CYTK's Projected Growth (PEG Ratio) (82.230) is slightly higher than the industry average of (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. P/S Ratio (128.205) is also within normal values, averaging (438.009).

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

A.I.Advisor
a Summary for NAMS with price predictions
Oct 22, 2026

NAMS's Indicator enters downward trend

The Aroon Indicator for NAMS entered a downward trend on October 14, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 166 similar instances where the Aroon Indicator formed such a pattern. In 141 of the 166 cases the stock moved lower. This puts the odds of a downward move at 85%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

Following a 3-day decline, the stock is projected to fall further. Considering past instances where NAMS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 78%.

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where NAMS's RSI Indicator exited the oversold zone, 25 of 27 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 90%.

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 48 of 60 cases where NAMS's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 80%.

The Momentum Indicator moved above the 0 level on October 22, 2026. You may want to consider a long position or call options on NAMS as a result. In 67 of 95 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 71%.

The Moving Average Convergence Divergence (MACD) for NAMS just turned positive on October 20, 2026. Looking at past instances where NAMS's MACD turned positive, the stock continued to rise in 38 of 57 cases over the following month. The odds of a continued upward trend are 67%.

Following a +8.42% 3-day Advance, the price is estimated to grow further. Considering data from situations where NAMS advanced for three days, in 199 of 247 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.

NAMS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 17 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 24 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.085) is normal, around the industry mean (2.973). P/E Ratio (-9.991) is within average values for comparable stocks, (-1.705). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. P/S Ratio (357.143) is also within normal values, averaging (438.009).

The Tickeron Profit vs. Risk Rating rating for this company is 65 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock slightly better than average.

The Tickeron Price Growth Rating for this company is 78 (best 1 - 100 worst), indicating slightly worse than average price growth. NAMS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

FUNDAMENTALS RATINGS
CYTK: Fundamental Ratings
CYTK
OUTLOOK RATING
1..100
7
VALUATION
overvalued / fair valued / undervalued
1..100
92
Overvalued
PROFIT vs RISK RATING
1..100
74
SMR RATING
1..100
100
PRICE GROWTH RATING
1..100
61
P/E GROWTH RATING
1..100
19
SEASONALITY SCORE
1..100
50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
CYTKNAMS
RSI
ODDS (%)
Bullish Trend 1 day ago
79%
Bullish Trend 1 day ago
90%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
76%
Bullish Trend 1 day ago
80%
Momentum
ODDS (%)
Bullish Trend 1 day ago
78%
Bullish Trend 1 day ago
71%
MACD
ODDS (%)
Bullish Trend 1 day ago
77%
Bullish Trend 1 day ago
67%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
78%
Bullish Trend 1 day ago
66%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
77%
Bearish Trend 1 day ago
71%
Advances
ODDS (%)
Bullish Trend 3 days ago
73%
Bullish Trend 3 days ago
81%
Declines
ODDS (%)
Bearish Trend 1 day ago
78%
Bearish Trend 9 days ago
78%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
73%
Bullish Trend 1 day ago
77%
Aroon
ODDS (%)
Bearish Trend 1 day ago
88%
Bearish Trend 1 day ago
85%
COMPARISON
Comparison
Oct 23, 2026
Stock price -- (CYTK: $62.33 vs. NAMS: $21.49)
Brand notoriety: CYTK and NAMS are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CYTK: 75% vs. NAMS: 89%
Market capitalization -- CYTK: $8.67B vs. NAMS: $2.58B
CYTK [@Biotechnology] is valued at $8.67B. NAMS’s [@Biotechnology] market capitalization is $2.58B. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $135.64B. The average market capitalization across the [@Biotechnology] industry is $2.14B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CYTK’s FA Score shows that 1 FA rating(s) are green while NAMS’s FA Score has 2 green FA rating(s).

  • CYTK’s FA Score: 1 green, 4 red.
  • NAMS’s FA Score: 2 green, 3 red.
According to our system of comparison, NAMS is a better buy in the long-term than CYTK.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CYTK’s TA Score shows that 6 TA indicator(s) are bullish while NAMS’s TA Score has 5 bullish TA indicator(s).

  • CYTK’s TA Score: 6 bullish, 3 bearish.
  • NAMS’s TA Score: 5 bullish, 3 bearish.
According to our system of comparison, CYTK is a better buy in the short-term than NAMS.

Price Growth

CYTK (@Biotechnology) experienced а -2.49% price change this week, while NAMS (@Biotechnology) price change was +7.40% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.17%. For the same industry, the average monthly price growth was -18.21%, and the average quarterly price growth was -15.24%.

Reported Earning Dates

CYTK is expected to report earnings on Nov 04, 2026.

NAMS is expected to report earnings on Nov 04, 2026.

Industries' Descriptions

@Biotechnology (-1.17% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
CYTK
Daily Signal:
Gain/Loss:
NAMS
Daily Signal:
Gain/Loss:
Interact to see
Advertisement

NAMS and

Correlation & Price change

A.I.dvisor indicates that over the last year, NAMS has been loosely correlated with VKTX. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if NAMS jumps, then VKTX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NAMS
1D Price
Change %
NAMS100%
+0.42%
VKTX - NAMS
45%
Loosely correlated
-2.08%
IMVT - NAMS
45%
Loosely correlated
+2.54%
PTCT - NAMS
43%
Loosely correlated
+0.67%
KURA - NAMS
42%
Loosely correlated
-0.20%
RAPP - NAMS
41%
Loosely correlated
+5.87%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
AMZD8.680.39
+4.70%
Direxion Daily AMZN Bear 1X ETF (AMZD)
LSAT47.681.06
+2.28%
Leadershares Alphafactor Tactical Focused ETF (LSAT)
USEP42.07-0.34
-0.80%
Innovator U.S. Equity Ultra Buffer ETF - September (USEP)
MDY664.00-5.42
-0.81%
State Street SPDR S&P MIDCAP 400 ETF Trust (MDY)
EIS120.12-1.96
-1.61%
iShares MSCI Israel ETF (EIS)